Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Enhancing Pathology Knowledge for Biomedical Scientists: Pilot Cohort Study of a Comprehensive Self-Paced Tutorial for Bridging Fundamental Concepts With Translational Applications.

JMIR medical education·2026
Same author

Comparison of imaging based single-cell resolution spatial transcriptomics profiling platforms using formalin-fixed paraffin-embedded tumor samples.

Nature communications·2025
Same author

CHD1 loss reprograms SREBP2-driven cholesterol synthesis to fuel androgen-responsive growth and castration resistance in SPOP-mutated prostate tumors.

Nature cancer·2025
Same author

Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations.

Molecular cancer therapeutics·2025
Same author

Accumulation of CD38 in Hybrid Epithelial/Mesenchymal Cells Promotes Immune Remodeling and Metastasis in Breast Cancer.

Cancer research·2025
Same author

Antitumor Activity and Biomarker Analysis for TROP2 Antibody-Drug Conjugate Datopotamab Deruxtecan in Patient-Derived Breast Cancer Xenograft Models.

Clinical cancer research : an official journal of the American Association for Cancer Research·2024

Related Experiment Video

Updated: Nov 15, 2025

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

10.8K

Pathology and Classification of SCLC.

Maria Gabriela Raso1, Neus Bota-Rabassedas1, Ignacio I Wistuba1

  • 1Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Cancers
|March 6, 2021
PubMed
Summary

Small cell lung carcinoma (SCLC) is an aggressive lung cancer subtype. This review covers SCLC pathology, immunohistochemistry, molecular features, and tumor microenvironment for new personalized therapy options.

Keywords:
biology of SCLCimmune-checkpoint inhibitors in SCLCpathology and classification of SCLC

More Related Videos

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.4K
Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

10.8K

Related Experiment Videos

Last Updated: Nov 15, 2025

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

10.8K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.4K
Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

10.8K

Area of Science:

  • Oncology
  • Pathology
  • Molecular Biology

Background:

  • Lung cancer is a leading cause of cancer death globally and the second most common cancer in the U.S.
  • Small cell lung carcinoma (SCLC) is an aggressive neuroendocrine lung cancer subtype, often diagnosed at advanced stages.
  • SCLC diagnosis typically relies on small biopsies and immunohistochemistry to identify neuroendocrine features.

Purpose of the Study:

  • To review the pathological features of SCLC.
  • To discuss clinically relevant immunohistochemistry markers and molecular characteristics.
  • To explore the tumor microenvironment and pathogenesis for novel therapeutic strategies.

Main Methods:

  • Review of existing literature on SCLC pathology and molecular biology.
  • Analysis of immunohistochemistry marker expression in SCLC.
  • Examination of tumor microenvironment and pathogenesis studies.

Main Results:

  • SCLC exhibits aggressive, poorly differentiated neuroendocrine carcinoma features.
  • Immunohistochemistry is crucial for SCLC diagnosis and differential diagnosis.
  • Understanding molecular characteristics and tumor microenvironment informs personalized therapy.

Conclusions:

  • SCLC remains a significant challenge due to its aggressive nature and advanced stage at diagnosis.
  • Advances in understanding SCLC pathology, molecular biology, and tumor microenvironment are paving the way for personalized treatment approaches.